Travere Therapeutics, Inc.
TVTX Nasdaq
SEC CIK 1438533
Follow Travere Therapeutics
Weekly email: filings, results
Revenue, last quarter
$224.6M
+36.2% vs same quarter last year
Net income
−$52.3M
−303.6% vs same quarter last year
EPS, diluted
−$0.55
−296.4% vs same quarter last year
Operating cash flow
$98.2M
+585.9% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $490.7M | −$25.5M |
| FY24 | $233.2M | −$321.5M |
| FY23 | $145.2M | −$111.4M |
| FY22 | $109.5M | −$278.5M |
| FY21 | $131.8M | −$180.1M |
| FY20 | $198.3M | −$169.4M |
| FY19 | $175.3M | −$146.4M |
| FY18 | $164.2M | −$102.7M |
| FY17 | $154.9M | −$59.7M |
| FY16 | $133.6M | −$47.9M |
| FY15 | $99.9M | $117.2M |
| FY14 | $28.2M | −$110.9M |
| FY13 | $0 | −$34.6M |
| FY12 | $0 | −$30.3M |
| FY11 | $0 | −$23K |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 97.9% | −12.8% | −5.2% |
| FY24 | 96.7% | −138.9% | −137.9% |
| FY23 | 92.1% | −267.2% | −76.7% |
| FY22 | 96% | −292.2% | −254.4% |
| FY21 | 97.1% | −151.3% | −136.6% |
| FY20 | 96.9% | −88.8% | −85.4% |
| FY19 | 97% | −78.3% | −83.5% |
| FY18 | 96.6% | −48.7% | −62.5% |
| FY17 | 97.7% | −34.7% | −38.6% |
| FY16 | 96.6% | −43.6% | −35.9% |
| FY15 | 97.8% | −50.8% | 117.4% |
| FY14 | 98% | −283% | −393.4% |
| FY13 | - | - | - |
| FY12 | - | - | - |
| FY11 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | −$280.7M |
| FY22 | −$186.5M |
| FY21 | −$19.9M |
| FY20 | −$49.5M |
| FY19 | −$58.4M |
| FY18 | −$25.7M |
| FY17 | $6.5M |
| FY16 | −$4.9M |
| FY15 | −$1.4M |
| FY14 | −$46.5M |
| FY13 | −$17.7M |
| FY12 | −$2.8M |
| FY11 | - |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | - |
| FY21 | - |
| FY20 | - |
| FY19 | - |
| FY18 | - |
| FY17 | - |
| FY16 | $0 |
| FY15 | $0 |
| FY14 | $2.3M |
| FY13 | $958K |
| FY12 | - |
| FY11 | - |
- Travere Therapeutics
- Healthcare median
Show the numbers
| Year | Travere Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −5.2% | −30.6% |
| FY24 | −137.9% | −47% |
| FY23 | −76.7% | −58% |
| FY22 | −254.4% | −80.4% |
| FY21 | −136.6% | −71.8% |
| FY20 | −85.4% | −62.2% |
| FY19 | −83.5% | −46.2% |
| FY18 | −62.5% | −49.6% |
| FY17 | −38.6% | −45.9% |
| FY16 | −35.9% | −36% |
| FY15 | 117.4% | −37.8% |
| FY14 | −393.4% | −35.5% |
| FY13 | - | −37.1% |
| FY12 | - | −29.1% |
| FY11 | - | −27.9% |